OBodies is a company formed by WaikatoLink Limited, the technology transfer office of the University of Waikato in Hamilton, New Zealand.
Their technologies will occupy part of the monoclonal antibody market, in addition to creating new markets through the ability to utilise OBodies in situations where traditional antibodies are unsuitable (for example, where heat stability is required).
OBodies platform technology has applications within:
- Clinical diagnostics
- Point of Care diagnostics
- Biotechnology research
- Industrial biotechnology
- Medical Therapeutics
The global diagnostic and therapeutic market is worth US$95 billion. Literally thousands of commercial applications exist for OBodies high affinity proteins, and it is estimated there are over 10,000 separate antibodies used in industrial research, clinical diagnostics and therapeutic applications today.
In late 2007 OBodies was successful in attracting investment from venture capital firm Endeavour Capital which has allowed the company to continue developing this leading edge technology.
We are interested in talking with industry partners about this leading edge technology.
To contact us please click here.